

Supplementary material

Pęksa JW, Storman D, Jankowski P, et al. Characteristics of hospitalized patients with established coronary artery disease and trends in their management — comparing 2013 and 2020. Kardiol Pol. 2022.

Please note that the journal is not responsible for the scientific accuracy or functionality of any supplementary material submitted by the authors. Any queries (except missing content) should be directed to the corresponding author of the article.

Table S1. Characteristics of patients, their in-hospital stay and comorbidities entered into medical records in history. Comparing patients hospitalized in 2013 vs. 2020

Year of admission	Mean (SD) or median (IQR), or proportion			
	2013	2020	P-value	P-value ^a
Total n of analyzed patients	142	103	—	
Age, years, median (IQR)	66.0 (60.0–74.0)	70.0 (64.0–75.0)	0.017	N/A
Male, n (%)	110 (77.5)	76 (73.8)	0.51	N/A
Length of stay, days, median (IQR)	3.0 (2.0–5.0)	3.0 (2.0–5.0)	0.87	0.99
Acute admission, n (%)	12 (8.5)	13 (12.6)	0.29	0.30
Leave, n (%)				
Home	138 (97.2)	98 (95.1)		
Transfer to other units	2 (1.4)	2 (1.9)	0.13	0.14
Transfer to other hospitals	0 (0.0)	3 (2.9)		
Death	2 (1.4)	0 (0.0)		
History of diseases / procedures in the past, before admission				
Hypertension, n (%)	138 (97.2)	99 (96.1)	0.64	0.53
Hypercholesterolemia, n (%)	140 (98.6)	103 (100.0)	0.23	0.26
Diabetes mellitus, n (%)	50 (35.2)	38 (36.9)	0.786	0.85
AF/AFL, n (%)	26 (18.3)	33 (32.0)	0.013	0.038
History of, n (%)				
AMI	65 (45.8)	39 (37.9)	0.22	0.16
PCI	63 (44.4)	39 (37.9)	0.31	0.40
CABG	8 (5.6)	6 (5.8)	0.95	0.91

Atherosclerosis of, n (%)				
Carotid arteries	6 (4.2)	8 (7.8)	0.24	0.30
Lower limb arteries	8 (5.6)	11 (10.7)	0.15	0.17
Stroke, n (%)	7 (4.9)	9 (8.7)	0.23	0.26
Non-CV operation, n (%)	31 (21.8)	52 (50.5)	<0.001	<0.001
Smoking \geq 10 pack-years, n (%)	53 (37.3)	56 (54.4)	0.008	0.001

^aAdjusted for age and sex

Abbreviations: AF, atrial fibrillation; AFL, atrial flutter; AMI, acute myocardial infarction; DSE, dobutamine stress echocardiogram; ECG, electrocardiography; EP, electrophysiological; FFR, fractional flow reserve; ICD, implantable cardioverter defibrillator; IQR, interquartile range; IVUS, intravascular ultrasound; N, number; N/A, not applicable; non-CV, non-cardiovascular; PCI, percutaneous coronary intervention; PM, pacemaker; SD, standard deviation; TTE, transthoracic echocardiography; USG, ultrasonography

Table S2. The frequency of entering anthropometric and blood pressure measurements into medical records, ordering given laboratory tests and procedures performed during stay in patients hospitalized in 2013 vs. 2020

Year of admission	Proportion			
	2013	2020	P-value	P-value ^a
Total n of analyzed patients	142	103	—	—
SBP, n (%)	140 (99.3)	103 (100.0)	0.39	0.54
DBP, n (%)	140 (99.3)	103 (100.0)	0.39	0.54
BMI, n (%)	128 (63.5)	54 (52.4)	0.09	0.10
Height, n (%)	85 (59.9)	40 (38.8)	0.001	0.001
Weight, n (%)	81 (57.0)	40 (38.8)	0.005	0.005
Laboratory parameters, n (%)				
HGB	141 (99.3)	103 (100.0)	0.39	0.31
WBC	141 (99.3)	103 (100.0)	0.39	0.31
PLT	141 (99.3)	103 (100.0)	0.39	0.31
TC	88 (62.0)	94 (91.3)	<0.001	<0.001
LDL-C	87 (61.3)	94 (91.3)	<0.001	<0.001

HDL-C	88 (62.0)	94 (91.3)	<0.001	<0.001
TG	88 (62.0)	94 (91.3)	<0.001	<0.001
FGL	81 (57.0)	82 (79.6)	<0.001	<0.001
HbA1c	0 (0.0)	35 (34.0)	<0.001	<0.001
Uric acid	29 (20.4)	75 (72.8)	<0.001	<0.001
Urea	141 (99.3)	103 (100)	0.39	0.32
Creatinine	142 (100.0)	103 (100)	—	—
Na+	141 (99.3)	102 (99.0)	0.82	0.90
K+	141 (99.3)	101 (98.1)	0.39	0.53
APTT	139 (97.9)	101 (98.1)	0.93	0.85
PT	141 (99.3)	102 (99.0)	0.82	0.73
INR	141 (99.3)	102 (99.0)	0.82	0.73
NT-proBNP	3 (2.1)	87 (84.5)	<0.001	<0.001
Procedure performed during stay (%)				
TTE	43 (30.3)	86 (83.5)	<0.001	<0.001
DSE	7 (4.9)	4 (3.9)	0.70	0.61
Carotid USG	5 (3.5)	10 (9.7)	0.046	0.050
Cardiac stress test	11 (7.7)	1 (1.0)	0.015	0.016
Coronary angiography	130 (91.5)	96 (93.2)	0.63	0.55
FFR	1 (0.7)	19 (18.4)	<0.001	<0.001
IVUS	2 (1.4)	5 (4.9)	0.11	0.14
PCI	59 (45.1)	42 (40.8)	0.50	0.61
PM (re)implantation	1 (0.7)	1 (1.0)	0.82	0.98
ICD (re)implantation	5 (3.5)	0 (0.0)	0.05	0.06
EP stud /cardiac ablation	0 (0.0)	0 (0.0)	—	—
Chest X-ray	34 (23.9)	25 (24.3)	0.95	0.85
ECG	133 (93.7)	95 (92.2)	0.66	0.58

^aAdjusted for age and sex

Abbreviations: APTT, activated partial thromboplastin time; BMI, body mass index; DBP, diastolic blood pressure; DSE, dobutamine stress echocardiogram; ECG, electrocardiography; EP, electrophysiological; FFR, fractional flow reserve; FGL, fasting glucose; HbA_{1c}, glycated hemoglobin; HDL-C, high-density lipoprotein cholesterol; HGB, haemoglobin; INR, international normalized ratio; IVUS, intravascular ultrasound; K⁺, potassium, ICD, implantable cardioverter defibrillator; LDL-C, low-density lipoprotein cholesterol; N – number, Na⁺, sodium; NT-proBNP, N-terminal prohormone of brain natriuretic peptide; PCI, percutaneous coronary intervention; PM, pacemaker; PLT, platelets count; PT, prothrombin time; SBP, systolic blood pressure; TC, total cholesterol; TG, triglycerides; TTE, transthoracic echocardiography; USG, ultrasonography; WBC, white blood cells count

Table S3. Medications prescribed at hospital discharge to patients hospitalized in 2020 vs. 2013

Year of admission	Proportion			
	2013	2020	<i>P</i> -value	<i>P</i> -value ^a
N of analyzed patients / total number of patients	139/142 ^b	103/103	—	—
Medications, n (%)				
ASA	128 (92.1)	86 (83.5)	0.039	0.06
Clopidogrel	77 (55.4)	47 (45.6)	0.13	0.19
Ticagrelor	0 (0.0)	4 (3.9)	0.019	0.008
BB	128 (92.1)	99 (96.1)	0.20	0.11
ACEI	108 (77.7)	70 (68.0)	0.09	0.12
ARB	18 (12.9)	21 (20.4)	0.12	0.20
MRA	17 (15.1)	15 (14.6)	0.91	0.69
CCB	43 (30.9)	40 (38.8)	0.20	0.22
Thiazide diuretics	13 (9.4)	8 (7.8)	0.67	0.66
Thiazide-like diuretics	34 (24.5)	20 (19.4)	0.35	0.35
Loop diuretics	37 (26.6)	37 (35.9)	0.12	0.29
Statins	132 (95.0)	101 (98.1)	0.21	0.18
Ezetimibe	2 (1.4)	17 (16.5)	<0.001	<0.001
Fibrates	5 (3.6)	2 (1.9)	0.45	0.58
Anti-diabetic drugs	41 (29.5)	39 (37.9)	0.17	0.20
Allopurinol	10 (7.2)	22 (21.4)	0.001	0.002
Trimetazidine	6 (4.3)	4 (3.9)	0.87	0.65
Nitrates	17 (12.2)	12 (11.7)	0.89	0.62
VKA	11 (7.9)	3 (2.9)	0.10	0.07
				<0.001

NOAC	12 (8.6)	28 (27.2)	<0.001	0.022
Rivaroxaban Vasc	0 (0.0)	3 (2.9)	0.043	0.55
LMWH	3 (2.2)	4 (3.9)	0.43	

^aAdjusted for age and sex

^b3 patients' discharge medications were not analyzed. In 2 of them there were no available data, third one died before discharge

Abbreviations: ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor

blockers; ASA, acetylsalicylic acid; BB, beta blockers; CCB, calcium channel blockers; LMWH,

low-molecular-weight heparin; MRA, mineralocorticoid receptor antagonists; N, number; NOAC,

non-vitamin-K oral anticoagulants; Rivaroxaban Vasc, Rivaroxaban in vascular dose; VKA, vitamin

K antagonists